SOCS1-derived peptide administered by eye drops prevents retinal neuroinflammation and vascular leakage in experimental diabetes
Hernández, Cristina (Universitat Autònoma de Barcelona. Departament de Medicina)
Bogdanov, Patricia (Hospital Universitari Vall d'Hebron)
Gómez-Guerrero, Carmen (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Sampedro, J. (Hospital Universitari Vall d'Hebron)
Solà-Adell, C. (Hospital Universitari Vall d'Hebron)
Espejo, Carmen (Hospital Universitari Vall d'Hebron)
Garcia-Ramírez, Marta (Hospital Universitari Vall d'Hebron)
Prieto, I. (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Egido, Jesús (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Simó, R. (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2019
Resum:	Current treatments for diabetic retinopathy (DR) target late stages when vision has already been significantly affected. Accumulating evidence suggests that neuroinflammation plays a major role in the pathogenesis of DR, resulting in the disruption of the blood-retinal barrier. Suppressors of cytokine signaling (SOCS) are cytokine-inducible proteins that function as a negative feedback loop regulating cytokine responses. On this basis, the aim of the present study was to evaluate the effect of a SOCS1-derived peptide administered by eye drops (2 weeks) on retinal neuroinflammation and early microvascular abnormalities in a db/db mouse model. In brief, we found that SOCS1-derived peptide significantly reduced glial activation and neural apoptosis induced by diabetes, as well as retinal levels of proinflammatory cytokines. Moreover, a significant improvement of electroretinogram parameters was observed, thus revealing a clear impact of the histological findings on global retinal function. Finally, SOCS1-derived peptide prevented the disruption of the blood-retinal barrier. Overall, our results suggest that topical administration of SOCS1-derived peptide is effective in preventing retinal neuroinflammation and early microvascular impairment. These findings could open up a new strategy for the treatment of early stages of DR.
Ajuts:	Ministerio de Economía y Competitividad PI16/00541 Ministerio de Economía y Competitividad SAF2015-63696-R Ministerio de Economía y Competitividad PI14/00386 Ministerio de Economía y Competitividad PI17/01495 Ministerio de Economía y Competitividad DTS-2017/00203 Ministerio de Economía y Competitividad BES-2013-064944
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	International journal of molecular sciences, Vol. 20 Núm. 15 (january 2019) , p. 3615, ISSN 1422-0067

DOI: 10.3390/ijms20153615
PMID: 31344857

20 p, 6.5 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats